EU Medicines Agencies Network Strategy to 2020

  • Email
  • Help

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have launched a public consultation on the European Union (EU) Medicines Agencies Network Strategy to 2020. This document outlines joint key priorities for the network and a high-level strategy to achieve these, for the first time.

The draft strategy focuses on areas where collaboration within the network can make a real difference to human and animal health in the EU over the five years to 2020. It builds on the EMA roadmap to 2015 and the HMA strategy document 2011-15.

The draft network strategy is arranged under four key themes focusing on:

  • human health;
  • animal health and human health in relation to veterinary medicines;
  • optimising the operation of the network;
  • the global regulatory environment.

Separate multi-annual work programmes and implementation plans for EMA, HMA, and the Coordination Groups for Mutual Recognition and Decentralised Procedures, Human and Veterinary (CMDh and CMDv) will be developed. These will give detailed information on the work of each component of the network and describe how the strategy will be taken forward.

The proposed strategy was released for consultation in March 2015 until 30 June 2015.

 EU medicines network strategy 2020

Road map 2010 – 2015

The Agency's Road map to 2015 set out the vision and priorities for the Agency for the period between 2010 and 2015.

The three priority areas outlined in the road map were:

  • addressing public health needs;
  • facilitating access to medicines;
  • optimising the safe and rational use of medicines.

The implementation plan of the road map, adopted in 2011, provides information on how the vision outlined in the road map had been developed gradually through its annual work programmes up to 2015.

Road map 2005 – 2010

In the Road map to 2010 the Agency set out its vision and priorities for the period between 2005 and 2010.

The three priority areas outlined in the road map were:

  • contributing to better protection and promotion of public and animal health;
  • improving the regulatory environment for medicinal products;
  • helping to stimulate innovation, research and development in the European Union.

How useful is this page?

Average rating:

 Based on 48 ratings

Add your rating:

See all ratings
40 ratings
1 ratings
1 ratings
4 ratings
2 ratings

External links

Related documents